Dementia and Alzheimer Disease

New study links serum-based liver function markers with known Alzheimer disease biomarkers.

The rationale for investigating monoclonal antibodies and BACE inhibitors for the treatment of patients with Alzheimer disease.

The International Congress on the Future of Neurology will take place this Fall in New York City, convening experts in neurology to discuss the latest data and best practices to better inform clinical decision-making.

Drs. Alireza Atri and Ronald C. Petersen remark on the important roles a community neurologist, as well as other members of a patient’s health care team, can play in the management of Alzheimer disease.

The fourth version of the Cleveland Clinic’s Alzheimer pipeline includes 156 clinical trials and 132 agents currently in all 3 phases of clinical trials in the US.

The role of clinical trials and the importance of counseling patients on trial enrollment and lifestyle interventions in the management of Alzheimer disease.

Expert clinicians highlight current unmet needs surrounding the treatment of Alzheimer disease.

Older patients could benefit from skipping traditional bedrest in favor of an exercise program when hospitalized with an acute illness.

Moving forward following failed studies in Alzheimer disease and improving how the condition is managed in the future.

An in-depth review of mechanisms linked to the pathogenesis of Alzheimer disease, including amyloid and tau.

Ronald C. Petersen, MD, PhD, discusses the relationship between genetics and the risk for developing Alzheimer disease, as well as highlights efforts of the Generation Program.

How improved telemedicine options could benefit the geriatric patient population and others who may not actually be suitable for emergency care situations.

How the thought of AD has changed to interpret the disease's pathology, and why that has benefitted clinicians.

AD symptoms can take years to manifest, making clinical trials difficult. Investigators are fixed on finding disease biomarkers.

What new drug classes are catching the most traction among clinicians?

Taking daily anticholinergic drugs when 55 or older increases the risk of dementia, according to this nested case-control study.

A new study from ATS showed an early symptom of Alzheimer disease is more prevalent in older patients with moderate OSA.

In a recent study, investigators from Europe found using virtual reality technology can have an impact on a patient's quality of life.

Investigators found significant changes in use of Alzheimer disease drug use, use of non-Alzheimer drug use, and counseling strategies among patients subsequent to amyloid PET.

One evaluated dose of AVP-786 significantly improved scores in patients with moderate-to-severe agitation related to Alzheimer dementia, compared to placebo.

A 16,000-patient assessment found that infection alone, excluding critical illness, is associated with reduced brain volume later in life.

The results of a new study point to age-related macular degeneration, diabetic retinopathy, and glaucoma as potential early warning signs that an individual is at risk for developing Alzheimer disease or dementia.

If done ethically, the genetic database's collaboration with GSK could provide researchers what they really need to improve neurological care: the right patients in the right studies.

An Alzheimer’s diagnosis may cause fear, but the broad spectrum of cognitive impairment means some physicians can continue to practice despite the disease.

A survey of beliefs about Alzheimer’s disease dementia identified the stigmas that pose a hurdle to clinical trials for therapies.